MYC and cancer: Previous studies showed that triptolide (TPL), a natural small molecule, exhibits potently cytocidal action against a subset of human cancer cells and induced rapid reduction of c‐Myc protein in sensitive cancer cells.[35, 36, 37] Triptolide was considered a promising anticancer agent, but its clinical use is largely limited due to poor aqueous solubility, dose‐limited toxicity, and the uncertainty of its antitumor targets.